SCID mice were treated with two weekly doses of 5 mg/kg DuoHexaBody-CD37 or PBS after tumors had established, and the ratio between the relative tumor growth in the DuoHexaBody-CD37-treated mouse (ΔT) and the PBS control mouse (ΔC) was used to classify responders (ΔT/ΔC < 10%) versus non-responders (ΔT/ΔC > 70%) and intermediates (10% ≤ ΔT/ΔC ≤ 70%). The gene discussed is CD37; the disease is neoplasm.